Daily supplement may ease MS fatigue

By Published On: 20 November 2026
Daily supplement may ease MS fatigue

A daily supplement was linked to a smaller rise in MS fatigue scores than placebo over 30 days in a trial involving 54 adults with multiple sclerosis (MS).

The supplement, called Familact, combines probiotics, live microorganisms thought to support gut health, with prebiotics, substances that help beneficial gut bacteria grow.

Researchers found that fatigue scores increased in both groups, indicating worsening fatigue, but the rise was significantly smaller among those taking Familact.

The trial, conducted at clinics affiliated with Arak University of Medical Sciences in Iran, involved 54 adults with relapsing-remitting MS who had not experienced a relapse in the previous three months.

Most were women, and their average age was 40.52 years.

Participants were randomly assigned to receive either 500 mg of Familact or a placebo daily for 30 days alongside their usual MS medications.

Familact contains nine bacterial strains, including species of Lactobacillus and Bifidobacterium, together with fructooligosaccharides, a type of plant-derived prebiotic.

Researchers measured fatigue using the Fatigue Severity Scale, a nine-question assessment of fatigue severity and its impact on everyday activities. Higher scores indicate more severe fatigue.

At the beginning of the trial, average fatigue scores were similar between the two groups.

After 30 days, both groups showed statistically significant increases in fatigue scores, reflecting worsening fatigue. However, the increase was significantly smaller among participants taking Familact.

Scores rose by an average of 2.23 points in the supplement group, compared with 5.44 points in the placebo group.

After accounting for initial fatigue scores, the researchers found that participants taking Familact had significantly lower average scores than those receiving the placebo, at 39.73 compared with 44.36.

The results therefore showed a smaller worsening of fatigue among those taking the supplement, rather than an improvement from their starting scores.

“The findings of this study highlighted the positive impact of probiotics and prebiotics with nine bacterial strains in alleviating fatigue in these patients,” the researchers wrote.

“While further research is required, these results open the door to exploring probiotic-based interventions for managing neurological disorders.”

No serious adverse reactions were reported during the study, and no participants experienced an MS relapse during or after the intervention.

MS occurs when the immune system attacks healthy tissue in the brain and spinal cord, disrupting the transmission of nerve signals.

Fatigue is a common symptom and can substantially affect quality of life and the ability to carry out everyday activities.

Research suggests that the gut microbiome, the community of microorganisms living in the digestive system, may contribute to inflammation associated with MS.

Probiotics may influence immune activity and inflammation by changing the balance of bacteria in the gut, potentially affecting factors associated with MS-related fatigue.

“These findings align with previous studies suggesting that probiotics may positively impact neurological conditions by influencing [blood] levels of factors associated with [body-wide] inflammation,” the researchers wrote.

However, the trial did not measure changes in gut bacteria or markers of inflammation, so the researchers could not establish why fatigue scores differed between the groups.

The study had several limitations, including its small sample size, short treatment period and recruitment of participants from a single country.

Possible differences in the demographic and clinical characteristics of the two groups at the start of the study may also have influenced the results.

The researchers said “caution should be exercised when interpreting the findings”.

The findings do not establish whether the difference in fatigue scores would persist beyond 30 days or whether similar results would be seen in people with other forms of MS.

“Further research involving larger, multicentre studies is necessary to validate these results and investigate the long-term effects of probiotic supplementation,” the researchers concluded.

Magnetic nanoparticles could offer less invasive Parkinson’s treatment
Post